Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Insulin Resistance
- Main trialPhase 2
- “This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.”In the company’s words, NCT05665751 on ClinicalTrials.gov
Other drugs for Insulin Resistance
- ObicetrapibNewAmsterdam Pharma · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- GZR4Gan & Lee · Phase 3
- EvexomostatSynDevRx, Inc. · Phase 1/2
- MOTS-cHudson Biotech · Phase 2
- AfrezzaMannkind Corporation · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Unknown | Sep 2024 | A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026